Bristol-Myers Squibb (NYSE:BMY) Shares Sold by ETF Managers Group LLC

ETF Managers Group LLC trimmed its position in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 17.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,836 shares of the biopharmaceutical company’s stock after selling 2,147 shares during the period. ETF Managers Group LLC’s holdings in Bristol-Myers Squibb were worth $708,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of BMY. True Wealth Design LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $26,000. Coppell Advisory Solutions Corp. acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $31,000. Live Oak Investment Partners acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $33,000. My Personal CFO LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $35,000. Finally, VitalStone Financial LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $36,000. 75.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Rupert Vessey sold 50,385 shares of the company’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $67.06, for a total value of $3,378,818.10. Following the transaction, the executive vice president now owns 47,751 shares of the company’s stock, valued at $3,202,182.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $66.16 on Friday. Bristol-Myers Squibb has a 12 month low of $63.07 and a 12 month high of $81.43. The stock has a market cap of $138.99 billion, a price-to-earnings ratio of 19.29, a PEG ratio of 1.33 and a beta of 0.44. The stock’s 50 day moving average price is $67.17 and its 200 day moving average price is $70.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.07. The company had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $11.50 billion. Bristol-Myers Squibb had a return on equity of 51.75% and a net margin of 15.95%. The firm’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.96 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 8.06 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th will be issued a $0.57 dividend. The ex-dividend date is Thursday, July 6th. This represents a $2.28 annualized dividend and a dividend yield of 3.45%. Bristol-Myers Squibb’s dividend payout ratio is currently 66.47%.

Wall Street Analyst Weigh In

BMY has been the subject of a number of research reports. StockNews.com initiated coverage on Bristol-Myers Squibb in a research note on Thursday, May 18th. They issued a “strong-buy” rating for the company. 51job reaffirmed a “maintains” rating on shares of Bristol-Myers Squibb in a report on Friday, April 28th. Jefferies Financial Group initiated coverage on Bristol-Myers Squibb in a report on Monday, March 6th. They set a “hold” rating and a $62.00 price target on the stock. Barclays cut their price target on Bristol-Myers Squibb from $66.00 to $65.00 in a report on Monday, May 1st. Finally, Bank of America lifted their price target on Bristol-Myers Squibb from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday, April 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.62.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Bristol-Myers Squibb, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Bristol-Myers Squibb wasn’t on the list.

While Bristol-Myers Squibb currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here